Capri­cor's DMD clin­i­cal tri­al meets pri­ma­ry end­points; Delaware court rules against Take­da in Lupron feud

Bev­er­ly Hills, CA-based biotech Capri­cor Ther­a­peu­tics re­vealed to­day fi­nal da­ta from its clin­i­cal tri­al eval­u­at­ing stem cell ther­a­py CAP-1002 for pa­tients in ad­vanced stages of Duchenne mus­cu­lar dy­s­tro­phy.

Duchenne is a rare mus­cle-wast­ing dis­ease caused by the ab­sence of dy­s­trophin, a pro­tein that helps keep mus­cle cells in­tact. It dis­pro­por­tion­ate­ly af­fects boys — and as of last year, af­fects rough­ly 6,000 in the Unit­ed States.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER